iBio (IBIO) to Release Earnings on Monday

iBio (NYSEAMERICAN:IBIO) is expected to be releasing its Q2 2026 results before the market opens on Monday, February 9th. Analysts expect iBio to post earnings of ($0.11) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Friday, February 13, 2026 at 9:30 AM ET.

iBio Stock Performance

IBIO opened at $2.42 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 0.91 and a current ratio of 0.91. iBio has a 1-year low of $0.56 and a 1-year high of $6.89. The firm has a 50-day moving average price of $2.04 and a two-hundred day moving average price of $1.33.

iBio Company Profile

iBio, Inc is a clinical-stage biotechnology company specializing in plant-based expression systems to develop and manufacture therapeutic proteins and vaccines. The company’s proprietary FastPharming™ technology harnesses a transient expression platform in plant cells, enabling rapid production of recombinant biologics. This approach is designed to offer an alternative to traditional mammalian or microbial cell culture systems, with potential benefits in speed, scalability and cost-effectiveness.

Through its iBio CDMO division, iBio provides contract development and manufacturing services to pharmaceutical and biotechnology clients.